Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06295965 | RECRUITING | Recurrent Fallopian Tube Carcinoma

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Sponsor:

University of Washington

Brief Summary:

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

Condition or disease

Recurrent Fallopian Tube Carcinoma

Recurrent Ovarian Carcinoma

Recurrent Primary Peritoneal Carcinoma

Recurrent Malignant Solid Neoplasm

Clonal Cytopenia of Undetermined Significance

Clonal Hematopoiesis

Idiopathic Cytopenia of Undetermined Significance

Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder

Ovarian Carcinoma

Myeloid Neoplasm Post Cytotoxic Therapy

Intervention/treatment

Non-Interventional Study

Detailed Description:

OUTLINE: This is an observational study. Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.

Study Type : OBSERVATIONAL
Estimated Enrollment : 2000 participants
Official Title : Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)
Actual Study Start Date : 2024-01-02
Estimated Primary Completion Date : 2028-12-31
Estimated Study Completion Date : 2031-12-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study:
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and
    • * Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy
    • OR
    • * Subjects who have or have had a solid tumor diagnosis and any of the following
      • * At least 4 months of exposure to a PARP inhibitor
      • * Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm
      Exclusion Criteria
      • * Individuals with a life expectancy of less than 6 months
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Location Details

NCT06295965

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Washington

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, United States, 98109